Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer.
Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN Jr, Van Veldhuizen PJ Jr, Quinn DI, Vogelzang NJ, Thompson IM Jr, Hussain MH. Dorff TB, et al. Among authors: quinn di. Clin Cancer Res. 2010 Jun 1;16(11):3028-34. doi: 10.1158/1078-0432.CCR-09-3122. Epub 2010 May 18. Clin Cancer Res. 2010. PMID: 20484019 Free PMC article. Clinical Trial.
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.
Lara PN Jr, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin R, Galvin I, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara DR; California Cancer Consortium. Lara PN Jr, et al. Among authors: quinn di. Clin Cancer Res. 2003 Oct 15;9(13):4772-81. Clin Cancer Res. 2003. PMID: 14581348 Clinical Trial.
Angiogenesis-targeted therapies in prostate cancer.
Lara PN Jr, Twardowski P, Quinn DI. Lara PN Jr, et al. Among authors: quinn di. Clin Prostate Cancer. 2004 Dec;3(3):165-73. doi: 10.3816/cgc.2004.n.027. Clin Prostate Cancer. 2004. PMID: 15636683 Review.
EphB4 expression and biological significance in prostate cancer.
Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI, Henshall SM, Sutherland RL, Pinski JK, Daneshmand S, Buscarini M, Stein JP, Zhong C, Broek D, Roy-Burman P, Gill PS. Xia G, et al. Among authors: quinn di. Cancer Res. 2005 Jun 1;65(11):4623-32. doi: 10.1158/0008-5472.CAN-04-2667. Cancer Res. 2005. PMID: 15930280
Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases.
Raghavan D, Brandes LJ, Klapp K, Snyder T, Styles E, Tsao-Wei D, Lieskovsky G, Quinn DI, Ramsey EW. Raghavan D, et al. Among authors: quinn di. J Urol. 2005 Nov;174(5):1808-13; discussion 1813. doi: 10.1097/01.ju.0000176799.63184.99. J Urol. 2005. PMID: 16217292 Clinical Trial.
275 results